Company Overview - Pluxee is a global leader in Employee Benefits and Engagement, operating in 29 countries with a focus on Meal & Food, Wellbeing, Lifestyle, Reward & Recognition, and Public Benefits [2] - The company serves over 500,000 clients, 37 million+ consumers, and 1.7 million+ merchants, supported by more than 5,000 team members and advanced technology [2] - Pluxee has been in business for over 45 years, emphasizing positive community impact, employee wellbeing, and environmental sustainability [2] Liquidity Contract Summary - As of December 31, 2024, the liquidity account held 200,439 Pluxee N.V. ordinary shares valued at €5,878,911 [4] - During the period from July 1, 2024, to December 31, 2024, the company purchased 972,323 ordinary shares worth €19,626,472 across 6,377 transactions and disposed of 848,300 ordinary shares worth €17,195,841 across 5,661 transactions [4] - In the previous half-yearly report as of June 30, 2024, the liquidity account held 59,130 Pluxee N.V. ordinary shares valued at €8,621,644 [4] - From January 31, 2024, to June 30, 2024, the company purchased 723,308 ordinary shares worth €19,930,588 across 5,132 transactions and disposed of 719,315 ordinary shares worth €19,933,554 across 4,627 transactions [4] - The liquidity account started with €10,000,000 as of January 31, 2024 [4]

Fiscal Q1 2025 Revenues Issy-les-Moulineaux, France – January 8th, 2025 A robust start to the year, in line with the Group's strategic and financial objectives Highlights Business momentum continuing to be strong in the first quarter, fueled by solid net retention and a development pipeline on track to meet full year objectivesTotal Revenues grew organically by +13.2% reaching 289 million euros in Fiscal Q1 2025, providing a solid foundation to achieve the low-double-digit growth target for the full yearOp ...

CARMIEL, Israel, Dec. 23, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its stockholders. December 23, 2024 Dear Protalix Stockholders, As we conclude 2024, I am filled with a ...

Voting results of the Fiscal 2024 Annual General Meeting of Pluxee Amsterdam-Schiphol, December 18, 2024 // Pluxee N.V. (“Pluxee”) held today its Annual General Meeting of Shareholders (“AGM”), in Amsterdam-Schipol, chaired by Didier Michaud Daniel, the Executive Chair of Pluxee’s Board of Directors. All resolutions on the agenda were approved by the shareholders. This included the adoption of the financial statements for the fiscal year which ended on August 31, 2024 (“Fiscal 2024”), and of the dividend d ...

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q3 2024 Results Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Mike Moyer - Investor Relations, LifeSci Advisors Dror Bashan - President and Chief Executive Officer Eyal Rubin - Senior Vice President and Chief Financial Officer Conference Call Participants John Vandermosten - Zacks Investment Research Daniel Smith - H.C. Wainwright & Co., LLC Robert Sassoon - Water Tower Research Operator Good morning, ladies and gentlemen, and welcome to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTALIX BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware __65-0643773__ (State ...

Exhibit 99.1 Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, November 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for ...

CARMIEL, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that Dror Bashan, the Company's President and Chief Executive Officer, will present live at the Life Sciences Investor Forum, hosted by VirtualInvestorConferences.com, on September 19, ...

Company is debt-free with no outstanding notes Balance sheet provides sufficient runway for ongoing operations CARMIEL, Israel, Sept. 3, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it has repaid in full all of the outstanding principal and interest paya ...

Protalix BioTherapeutics, Inc. (NYSE:PLX) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Mike Moyer - Managing Director, LifeSci Advisors Dror Bashan - President and CEO Eyal Rubin - SVP and CFO Conference Call Participants John Vandermosten - Zacks Small Cap Research Unidentified Analyst - H.C. Wainwright Operator Good morning, ladies and gentlemen and welcome to the Protalix BioTherapeutics Second Quarter 2024 Financial and Business Results Conference Call. As a reminder, ...